Advances in the management of Pseudomonas aeruginosa infections in cancer patients.
D002228:Carbenicillin / Q000627:therapeutic use; D003091:Colistin / Q000627:therapeutic use; D004473:Ecthyma / Q000209:etiology; D005839:Gentamicins / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000150:complications*; D007945:Leukemia, Lymphoid / Q000150:complications; D008223:Lymphoma / Q000150:complications; D008581:Meningitis / Q000209:etiology; D009503:Neutropenia / Q000150:complications; D011014:Pneumonia / Q000209:etiology; D011113:Polymyxins / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa; D018805:Sepsis / Q000188:drug therapy; D014511:Uremia / Q000139:chemically induced
D005839:Gentamicins; D011113:Polymyxins; D002228:Carbenicillin; D003091:Colistin